Unusual items boosting Royalty Pharma's profit may not recur, possibly causing a profit drop this year. The company's statutory earnings may not truly reflect its underlying earnings power. Investors should note 4 warning signs for Royalty Pharma.

Significant insider share selling might worry some shareholders despite the implication of the company acting in all shareholders' interest. The overall analysis of insider transactions, however, lacks confidence.